Congress mandates pediatric cancer studies for adult drugs, extends pharma voucher program

What it does

This bill amends federal drug-approval rules to require pharmaceutical companies developing molecularly targeted cancer drugs to conduct pediatric studies as a condition of adult approval. It also extends the 'priority review voucher' program—which gives companies expedited FDA review in exchange for developing rare pediatric disease treatments—through 2030, and mandates congressional reports on whether these incentives actually produce new pediatric cancer and rare-disease drugs.

Why we flagged it

The bill's core mechanism is a regulatory requirement for pediatric cancer studies plus an extension of a tradeable FDA voucher program. Both are designed to incentivize pharmaceutical development for pediatric indications, not a general public-health mandate or restriction.

What the text implies

• The priority review voucher is tradeable and may be sold to large pharmaceutical firms, concentrating regulatory benefits among companies with capital to acquire vouchers rather than those developing the treatments.
• The 3-year implementation delay allows industry to prepare and potentially structure applications to minimize pediatric study burdens, reducing the practical impact of the pediatric cancer requirement.
• The bill requires FDA coordination with industry on implementation but does not establish enforcement mechanisms if companies fail to conduct adequate pediatric studies or if studies are delayed.
• GAO reports are due 5–10 years after enactment, creating a long lag before Congress can assess whether the incentives actually produced new pediatric treatments or merely redistributed regulatory benefits.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands FDA authority to require pediatric cancer drug studies, ensuring children have access to treatments developed for adults and addressing a genuine gap in pediatric oncology data. The priority voucher extension incentivizes rare pediatric disease development. However, the voucher mechanism creates a tradeable regulatory benefit that may be captured by large firms, and the 3-year implementation delay and reliance on industry coordination introduce execution risk.

Who stands to gain

• pharmaceutical companies developing molecularly targeted cancer drugs
• companies acquiring priority review vouchers
• large-cap pharma firms with capital to invest in pediatric oncology programs

Named in the bill

FDA, HHS, Comptroller General, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce

Where it stands

37 cosponsors: 20 Democrats, 17 Republicans.

• Dec 2, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Dec 2, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $144,000 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Markwayne Mullin, the sponsor, reported $979,756 in PAC receipts in the 2026 cycle.

• Biotechnology Innovation Organization — $60,000 on 1 filing
• Glaukos Corporation — $60,000 on 1 filing
• Rafael Holdings, Inc. — $24,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.